<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261116</url>
  </required_header>
  <id_info>
    <org_study_id>502.402</org_study_id>
    <nct_id>NCT02261116</nct_id>
  </id_info>
  <brief_title>Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers</brief_title>
  <official_title>Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess potential different properties of telmisartan, which due to its Vd, should&#xD;
      result in stronger &quot;beneficial&quot; effects of AT1 blockade in tissues (e.g. aldosterone&#xD;
      suppression and renin increase) plus stronger AT2 stimulation compared to candesartan&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slope of PRA increase versus DR-1</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
    <description>analysis of variance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of angiotensin-1 (AT1) pressor antagonism in vivo (DR-1)</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
    <description>rightward shift (DR-1) of diastolic blood pressure response to Angiotensin II dose escalating challenges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma aldosterone concentration after stimulation with Angiotensin II</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive response of the plasma renin activity (PRA)</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <arm_group_label>Candesartan</arm_group_label>
    <other_name>Blopress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males, aged 18 to 45 years.&#xD;
&#xD;
          2. Absence of any relevant disease as determined by no clinically deviation from normal&#xD;
             in medical history, clinical laboratory determination, ECGs and physical examinations&#xD;
&#xD;
          3. Systolic blood pressure (SBP) between 100 and 140 mmHg systolic and below 85 mmHg&#xD;
             diastolic (both left and right arm) and a heart rate of ≥50 bpm&#xD;
&#xD;
          4. Signed informed consent form&#xD;
&#xD;
          5. No intake of drugs inbetween a waiting time of ten times of half-life&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to Ang II antagonists, known hypersensitivity, history of&#xD;
             angioedema, serious allergy, asthma, allergic skin rash, significant allergic rhinitis&#xD;
             or sensitivity to any drug&#xD;
&#xD;
          2. History of cardiovascular diseases: any clinically significant cardio-vascular&#xD;
             disease, a supine diastolic blood pressure &gt;86 mmHg and systolic &gt;141 mmHg measured by&#xD;
             a standard sphygmomanometer or a heart rate ≤49 bpm&#xD;
&#xD;
          3. Cerebrovascular diseases: history of stroke or transitory ischemic attacks (TIAs) or&#xD;
             history of any cerebral bleeding&#xD;
&#xD;
          4. Renal diseases: serum creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          5. Gastrointestinal/Hepatic diseases: Aspartate aminotransferase (ASAT) &gt;40 U/l or&#xD;
             Alanine aminotransferase (ALAT) &gt;40 U/L, serum bilirubin &gt;2x upper limit of normal,&#xD;
             history of malabsorption or inability to tolerate oral medication, history of gastric&#xD;
             or duodenal ulcers, history of significant gastrointestinal bleeding, history of&#xD;
             hepatitis within the past years&#xD;
&#xD;
          6. Any history of alcohol or drug abuse&#xD;
&#xD;
          7. Use of any of the following drugs within 4 weeks of study enrolment (e.g. agents known&#xD;
             to induce drug metabolizing enzymes): anabolic steroids and corticoids,&#xD;
             antiarrhythmics (amiodarone, mexiletine, quinidine, propafenone), antibiotics&#xD;
             (chloramphenicol, tetracyclines, sulfonamides, macrolides, cephalosporins, rifampicin,&#xD;
             nalidixic acid), antiepileptics (phenytoin, carbamazepine), antifungals (e.g.&#xD;
             griseofulvin), barbiturates, cimetidine, ethacrynic acid, fibrates, furosemide,&#xD;
             haloperidol, lipid lowering agents (cholestyramine, hydroxymethylglutaryl, coenzyme A&#xD;
             (HMG CoA) reductase inhibitors, dextrothyroxin), thyroid replacement therapy hormones&#xD;
             or thyrostatics (thioureylene-type). The use of nonsteroidal antiinflammatory drugs&#xD;
             (NSAIDs) should be discontinued 2 weeks prior to study enrolment, the one exception of&#xD;
             aspirin should be one (1) week prior to study enrolment&#xD;
&#xD;
          8. Participation in any other investigational study, within the 30 days prior to&#xD;
             enrolment&#xD;
&#xD;
          9. Blood donation within the previous 3 months&#xD;
&#xD;
         10. The investigator might disqualify a subject for a sound medical or psychiatric reason&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

